Beyond weight loss: protecting muscle with GLP-1s. Dr Almandoz shares strategies to preserve muscle, optimize body composition, and enhance health outcomes during GLP-1 therapy.

as prior studies have reported GLP-1 receptor agonist discontinuation rates of up to 81%, Emanuel's group wrote. They added that the links between weight loss and discontinuation and between ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic ...

The rise of GLP-1 agonist weight loss drugs has prompted the supplement industry to launch a bevy of “natural alternatives” to pharmaceutical compounds like Ozempic and Wegovy. But do they ...

“The rapid evolution of the pharmaceutical industry, particularly in the growing weight loss and diabetes and obesity treatment market, underscores the critical role of innovation and the need ...

including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs. However, the new study led by Ziyad Al-Aly, a physician-scientist at the Veterans Affairs St ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...